Home > Insider Trading > Filing (0001209191-19-043912)

Filing Details

Accession Number:: 0001209191-19-043912
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-07-31 18:48:01
Reporting Period:: 2019-07-29

Accepted Time:: 2019-07-31 18:48:01
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1447362	Castle Biosciences Inc	CSTL	Pharmaceutical Preparations (2834)	CA

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1024008	S David Kabakoff	C/O Castle Biosciences, Inc. 820 S. Friendswood Drive, Suite 201 Friendswood TX 77546		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-07-29	1,676,061	$0.00	1,676,061	No	4	C	Indirect	By L.P.
Common Stock	Acquisiton	2019-07-29	83,453	$12.80	1,759,514	No	4	C	Indirect	By L.P.
Common Stock	Acquisiton	2019-07-29	11,572	$0.02	1,771,086	No	4	X	Indirect	By L.P.
Common Stock	Disposition	2019-07-29	9	$16.00	1,771,077	No	4	S	Indirect	By L.P.
Common Stock	Acquisiton	2019-07-29	62,500	$16.00	1,833,577	No	4	P	Indirect	By L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By L.P.
No	4	C	Indirect	By L.P.
No	4	X	Indirect	By L.P.
No	4	S	Indirect	By L.P.
No	4	P	Indirect	By L.P.

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2019-07-29	19,524	$0.00	16,015	$0.00
Common Stock	Series E-2 Preferred Stock	Disposition	2019-07-29	436,910	$0.00	358,416	$0.00
Common Stock	Series E-3 Preferred Stock	Disposition	2019-07-29	388,669	$0.00	318,842	$0.00
Common Stock	Series F Preferred Stock	Disposition	2019-07-29	1,198,016	$0.00	982,785	$0.00
Common Stock	Convertible Promissory Note	Disposition	2019-07-29	0	$0.00	83,453	$12.80
Common Stock	Warrant to purchase Series F Preferred Stock	Disposition	2019-07-29	14,107	$0.00	11,572	$0.02

Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
	No	4	C	Indirect
	No	4	C	Indirect
	No	4	C	Indirect
	No	4	C	Indirect
	No	4	C	Indirect
2019-07-29	No	4	X	Indirect

Footnotes

The shares of Common Stock issued upon conversion of the Preferred Stock were calculated by first aggregating all series of Preferred Stockheld by the Reporting Person, in accordance with the terms of the Company's then-effective Certificate of Incorporation.
Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date.
Held by Sofinnova HealthQuest Partners, L.P., or HealthQuest Partners. HealthQuest Venture Management, L.L.C., or HealthQuest Management, is the managing member of HealthQuest Partners. David Kabakoff, Ph.D., the Reporting Person, is a partner of HealthQuest Management. Garheng Kong is the managing member of HealthQuest Management and has sole voting and investment power over the shares held by HealthQuest Partners. Each of HealthQuest Management, Mr. Kong and Dr. Kabakoff disclaims beneficial ownership over all shares held by HealthQuest Partners except to the extent of any pecuniary interest therein.
The principal amount of the Convertible Promissory Note held by HealthQuest Partners was $1,027,882. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 80% of the IPO price per share of $16.00 per share.
On July 29, 2019, the reporting person exercised a warrant to purchase 11,572 shares of the Issuer's common stock for approximately $0.02 per share. The reporting person paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 9 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 11,563 shares.
Represents a purchase from the underwriters in the Issuer's IPO.
Immediately prior to the closing of the IPO, the warrant became exercisable for 11,572 shares of Common Stock.
Immediately exercisable.